| Title |
Calcium channel blockers for neuroleptic-induced tardive dyskinesia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2011
|
| DOI | 10.1002/14651858.cd000206.pub3 |
| Pubmed ID | |
| Authors |
Adib Essali, Hany Deirawan, Karla Soares-Weiser, Clive E Adams |
| Abstract |
Schizophrenia and related disorders affect a sizable proportion of any population. Neuroleptic (antipsychotic) medications are the primary treatment for these disorders. Neuroleptic medications are associated with a variety of side effects including tardive dyskinesia. Dyskinesia is a disfiguring movement disorder of the orofacial region that can be tardive (having a slow or belated onset). Tardive dyskinesia is difficult to treat, despite experimentation with several treatments. Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil) have been among these experimental treatments. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 17% |
| Chile | 1 | 17% |
| United Kingdom | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 1% |
| Unknown | 68 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 17% |
| Researcher | 11 | 16% |
| Other | 10 | 14% |
| Student > Master | 9 | 13% |
| Student > Doctoral Student | 7 | 10% |
| Other | 14 | 20% |
| Unknown | 6 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 35% |
| Psychology | 11 | 16% |
| Social Sciences | 5 | 7% |
| Neuroscience | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 14 | 20% |
| Unknown | 8 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2017.
All research outputs
#5,495,075
of 22,774,233 outputs
Outputs from Cochrane database of systematic reviews
#7,332
of 12,314 outputs
Outputs of similar age
#33,901
of 143,051 outputs
Outputs of similar age from Cochrane database of systematic reviews
#87
of 154 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.4. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,051 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 154 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.